Trial reportPsychopharmacology2009
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans.
Trial report in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00606892 (Varenicline Attenuates Some of the Subjective and Physiological Effects of Intravenous Nicotine in Humans.), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Varenicline Attenuates Some of the Subjective and Physiological Effects of Intravenous Nicotine in Humans.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial.Addiction (Abingdon, England) · 2025Trial
- Efficacy and safety of combination behavioral activation for smoking cessation and varenicline for treating tobacco dependence among individuals with current or past major depressive disorder: A 2 × 2 factorial, randomized, placebo-controlled trial.Addiction (Abingdon, England) · 2023Trial
- Effect of varenicline on aspects of inhibitory control in smokers.Psychopharmacology · 2014Trial
- Dissociable effect of acute varenicline on tonic versus cue-provoked craving in non-treatment-motivated heavy smokers.Drug and alcohol dependence · 2013Trial
- Individual differences in amygdala reactivity following nicotinic receptor stimulation in abstinent smokers.NeuroImage · 2013Trial
- Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.Journal of psychopharmacology (Oxford, England) · 2012Trial
- Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.Experimental and clinical psychopharmacology · 2012Trial
- Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.Archives of general psychiatry · 2011Trial
- Changes in distinct brain systems identified with fMRI during smoking cessation treatment with varenicline: a review.Psychopharmacology · 2024Review
- Anhedonia and the relative reward value of drug and nondrug reinforcers in cigarette smokers.Journal of abnormal psychology · 2014Article
- Future pharmacological treatments for substance use disorders.British journal of clinical pharmacology · 2014Review
- Ro 32-0432 attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
- Biomarkers to optimize the treatment of nicotine dependence.Biomarkers in medicine · 2011Review
- Varenicline increases smoking abstinence at 6 months to a year compared with placebo or bupropion; nausea is the most commonly reported adverse effect.Evidence-based medicine · 2011Article
- Varenicline for tobacco dependence: panacea or plight?Expert opinion on pharmacotherapy · 2011Review
- Cognitive enhancers in the treatment of substance use disorders: clinical evidence.Pharmacology, biochemistry, and behavior · 2011Review
- Review
- Comparison of available treatments for tobacco addiction.Current psychiatry reports · 2010Review
- Cognitive effects of nicotine: genetic moderators.Addiction biology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
rationaleVarenicline, a partial nicotinic acetylcholine receptor (nAChR) agonist, is approved for smoking cessation. A few preclinical studies examined the pharmacological effects of varenicline, alone or in combination with nicotine. How varenicline affects the pharmacological effects of pure nicotine has not been examined in humans. The goal of this study was to characterize varenicline's actions on nicotine's dose-dependent effects in abstinent smokers.
methodsSix male and six female smokers participated in a double-blind, placebo-controlled, crossover study. Smokers had two 4-day treatment periods, assigned in random sequence, to varenicline (1 mg/day) or placebo treatment. On day 4 of each treatment phase, smokers had an experimental session, where they received three escalating doses of intravenous (IV) nicotine (0.1, 0.4, and 0.7 mg/70 kg), in 30-min intervals. Varenicline's effects were assessed through subjective, physiological, and cognitive performance outcomes to nicotine administered via IV route.
resultsIn response to IV nicotine, varenicline treatment attenuated the rating of drug strength, high, head rush, and stimulated. Varenicline also attenuated nicotine-induced increases in heart rate. Varenicline had mixed effects on cognitive performance. Smokers under varenicline treatment, compared with placebo, reported enhanced positive mood measured with the Positive and Negative Affect Schedule.
conclusionsThese findings provide new insights into the mechanisms of action of varenicline in smoking cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.